Celea Therapeutics
Summary active Updated Jul 3, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Celea Therapeutics is a PureTech Health founded entity spun out in 2025 to advance deupirfenidone (LYT-100), a next-generation antifibrotic being developed as a potential new standard of care for idiopathic pulmonary fibrosis (IPF) 12. On 2026-07-02 Celea announced completion of a $180M financing to fund the Phase 3 SURPASS-IPF trial, with an initial $75M closed on 2026-06-29 in Series Seed Preferred stock at $1.93 per share and the remainder committed by additional investors 12. Participants include RA Capital Management, Leaps by Bayer, PureTech Health (which contributed $30M and retains 35.4% of fully diluted share capital), an unnamed large U.S. healthcare-focused fund, and a leading sovereign wealth fund 123.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-02 | Series Seed | $180M | RA Capital Management, Leaps by Bayer, PureTech Health | undisclosed US healthcare fund, undisclosed sovereign wealth fund 123 |
What Investors Say
Laura Stoppel, RA Capital Management: “The compelling results generated to date with deupirfenidone and the Company’s bold Phase 3 SURPASS-IPF trial represent a differentiated opportunity to meaningfully change the treatment landscape in IPF” 1.
Robert Lyne, CEO of PureTech Health: “The completion of Celea’s $180 million financing marks a transformative milestone for both PureTech and Celea” 1.
What Founders Say
Sven Dethlefs, CEO of Celea: “We are grateful for the support and confidence of this exceptional group of investors, whose commitment enables us to initiate the Phase 3 SURPASS-IPF trial” 1.
Sources
-
BioSpace, “PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF),” July 2, 2026. Accessed July 2026. https://www.biospace.com/press-releases/puretech-founded-entity-celea-therapeutics-completes-180-million-financing-to-advance-deupirfenidone-as-a-potential-new-standard-of-care-to-treat-idiopathic-pulmonary-fibrosis-ipf↩↩↩↩↩↩↩
-
BioPharma Dive, “A PureTech startup banks $180M for a new IPF drug,” July 2, 2026. Accessed July 2026. https://www.biopharmadive.com/news/celea-puretech-idiopathic-pulmonary-fibrosis-raise/824330/↩↩↩↩
-
FinSMEs, “Celea Therapeutics Raises $180M in Financing,” July 2026. Accessed July 2026. https://www.finsmes.com/2026/07/celea-therapeutics-raises-180m-in-financing.html↩↩